United States Drug Patent 6,287,539: Scope, Claims, and Landscape Analysis
United States Patent 6,287,539, titled "Substituted 1,3-dihydro-2H-imidazol-2-one derivatives," was granted on September 11, 2001, to Merck & Co., Inc. The patent covers a class of chemical compounds and their use in treating hypertension. The disclosed compounds are characterized by a specific structural formula, with variations at certain positions allowing for a range of related molecules. The patent's claims define the scope of protection for these chemical entities, their pharmaceutical compositions, and methods of their use.
What is the Core Invention of Patent 6,287,539?
The patent protects novel substituted 1,3-dihydro-2H-imidazol-2-one derivatives. These compounds act as endothelin receptor antagonists. Endothelin is a peptide that plays a significant role in the regulation of blood pressure and vascular tone. By blocking the action of endothelin at its receptors, these compounds can lead to vasodilation, thereby reducing blood pressure.
The primary structural features of the claimed compounds are:
- A central 1,3-dihydro-2H-imidazol-2-one core: This bicyclic ring system is fundamental to the structure.
- Substitutions at specific positions: The patent defines permissible substituents at positions 3, 4, and 5 of the imidazolone ring, and on an attached aryl or heteroaryl group. These substitutions modulate the compound's affinity for the endothelin receptor, pharmacokinetic properties, and overall efficacy.
A representative structure from the patent is depicted as follows:
R1
|
N--C--N
/ \ / \
C---C---C=O
| | |
R2 R3 R4
Where R1, R2, R3, and R4 represent various chemical groups as defined in the patent claims.
What are the Key Claims Protected by the Patent?
United States Patent 6,287,539 contains multiple claims defining the scope of protection. These claims are hierarchical, with independent claims establishing the broadest protection and dependent claims narrowing the scope to specific embodiments.
Independent Claims:
- Claim 1: This claim defines the core chemical structure of the substituted 1,3-dihydro-2H-imidazol-2-one derivatives. It specifies the permissible substituents for R1, R2, R3, and R4, encompassing a broad range of chemical moieties designed to interact with endothelin receptors. For example, R1 can be a hydrogen atom or a hydrocarbon radical, R2 can be an aryl or heteroaryl group substituted with various functional groups, and R3 and R4 are further defined.
- Claim 2: This claim covers pharmaceutical compositions containing at least one compound according to claim 1 and a pharmaceutically acceptable carrier. This claim broadens the protection beyond the active pharmaceutical ingredient (API) itself to include its formulation into a medicinal product.
- Claim 3: This claim describes a method of treating hypertension in a mammal. It involves administering a therapeutically effective amount of at least one compound according to claim 1. This claim protects the therapeutic application of the patented compounds.
Dependent Claims (Examples):
Dependent claims refine the scope of the independent claims by specifying particular substituents or combinations thereof. For instance, they might:
- Restrict the nature of the aryl or heteroaryl group in R2.
- Define specific functional groups attached to the aryl or heteroaryl substituent.
- Specify the type of hydrocarbon radical for R1.
- Detail particular salts or solvates of the claimed compounds.
These dependent claims provide fallback positions and further define specific, potentially more potent or safer, embodiments of the invention.
What is the Scope of the Patent's Composition Claims?
The composition claims in patent 6,287,539 protect not only the novel chemical entities themselves but also their incorporation into pharmaceutical products.
- Claim 1 defines the molecular structures. This includes the specific atoms, their arrangement, and the types and positions of substituents. Protection extends to any compound that falls within the structural parameters defined by the claim.
- Claim 2 protects pharmaceutical formulations. This means that any preparation containing one or more of the claimed compounds along with inert ingredients (carriers, excipients, binders, etc.) intended for medical use is covered. This is crucial as it prevents competitors from marketing the patented drug even if they use different inactive ingredients.
The scope of these claims is determined by the precise wording and the definitions of the variable substituents. A thorough understanding of organic chemistry nomenclature and the specific definitions provided within the patent document is necessary to accurately ascertain what falls within or outside the scope of protection.
What is the Scope of the Patent's Method of Use Claims?
The method of use claims in patent 6,287,539 protect the therapeutic application of the patented compounds.
- Claim 3 and its dependent claims define the treatment of hypertension. This means that any entity using one of the patented compounds to treat hypertension, regardless of who manufactured the compound, could potentially infringe. This is particularly relevant for generic manufacturers seeking to market a drug after patent expiry.
The efficacy of the compounds as endothelin receptor antagonists and their consequent ability to lower blood pressure are central to these claims. The claims typically specify administering a "therapeutically effective amount," which refers to the dosage and frequency required to achieve the desired therapeutic outcome.
How Does Patent 6,287,539 Relate to Existing Endothelin Receptor Antagonists?
The patent landscape for endothelin receptor antagonists is competitive. Several compounds targeting this pathway have been developed and patented.
Key Endothelin Receptor Antagonists:
- Bosentan (Tracleer): This was one of the first endothelin receptor antagonists approved for use, primarily for pulmonary arterial hypertension (PAH). It is a dual endothelin receptor antagonist (ETA and ETB). (US Patent 5,292,747)
- Ambrisentan (Letairis): Also approved for PAH, ambrisentan is a selective ETA receptor antagonist. (US Patent 5,972,916)
- Macitentan (Opsumit): Another dual ETA/ETB receptor antagonist used for PAH. (US Patent 7,846,952)
Patent 6,287,539 is distinct from these earlier patents due to its specific chemical structure and claims. The compounds described in 6,287,539 are characterized by the 1,3-dihydro-2H-imidazol-2-one core, which differentiates them structurally from bosentan, ambrisentan, and macitentan, which have different core scaffolds.
The novelty and non-obviousness of the compounds described in patent 6,287,539, as assessed during the patent examination process, would have been critical for its grant. This implies that the claimed structures are not merely minor variations of known endothelin receptor antagonists but represent a distinct chemical class.
What is the Status of Patent 6,287,539?
The patent was granted on September 11, 2001. In the United States, utility patents typically have a term of 20 years from the date of filing. For applications filed before June 8, 1995, the term was 17 years from the grant date. For applications filed on or after June 8, 1995, the term is 20 years from the filing date.
Assuming a filing date that falls under the post-June 8, 1995 rules, the 20-year term from the filing date would have commenced prior to the grant date. Therefore, the patent's term has likely expired or is very close to expiring.
Patent Term Calculation Example:
- Filing Date: Assume filing date was March 15, 1998.
- Grant Date: September 11, 2001.
- Patent Term: 20 years from filing date = March 15, 2018.
Verification of the exact filing date and any potential patent term extensions (PTE) or adjustments (PTA) would be necessary for precise expiration dating. However, for patents granted in 2001, the original 20-year term is likely concluded.
What are the Potential Infringement Considerations?
Entities developing or marketing hypertension treatments need to carefully assess potential infringement of patent 6,287,539.
Key considerations include:
- Structural Identity/Similarity: Does a new compound fall within the precise structural definitions of Claim 1? This involves analyzing all substituents and ensuring they meet the specified criteria.
- Claim Construction: The interpretation of the patent claims, especially the definitions of variable substituents and functional groups, is critical. This is often a subject of litigation.
- Method of Use: If a compound, even one not structurally identical to those in Claim 1, is found to act as an endothelin receptor antagonist and is used to treat hypertension, it could potentially be implicated under the method of use claims.
- Generic Drug Development: As the patent term approaches expiration, generic manufacturers will analyze the patent landscape to ensure their proposed generic product does not infringe any active patents. This includes analyzing the original innovator's patents and any related patents that may have been filed.
- Evergreening: While the primary term of this patent is likely expired, companies sometimes file new patents on formulations, new uses, or specific polymorphs of existing drugs to extend market exclusivity.
Who is the Assignee?
The assignee of United States Patent 6,287,539 is Merck & Co., Inc. This indicates that Merck & Co., Inc. held the rights to this invention and was responsible for its prosecution and maintenance. Merck has a significant research and development pipeline in the cardiovascular therapeutic area.
What is the Commercial Relevance of the Invention?
The invention's relevance lies in its potential to treat hypertension, a prevalent chronic condition affecting millions worldwide. Endothelin receptor antagonism represents a significant pharmacological pathway for blood pressure control.
While specific commercial products directly stemming from this patent are not immediately evident in major market databases under this patent number, the research it represents contributes to the broader understanding and development of endothelin receptor antagonists. Such research can inform the design of subsequent generations of drugs with improved efficacy, safety profiles, or alternative therapeutic applications beyond hypertension, such as pulmonary arterial hypertension (PAH) or certain fibrotic diseases.
The compounds and their therapeutic approach are part of a broader effort to develop novel cardiovascular drugs.
What are the Key Takeaways?
- United States Patent 6,287,539 protects substituted 1,3-dihydro-2H-imidazol-2-one derivatives acting as endothelin receptor antagonists for treating hypertension.
- The patent's claims define specific chemical structures, pharmaceutical compositions containing these structures, and methods of using them to treat hypertension.
- The patent is distinct from other major endothelin receptor antagonists like bosentan and ambrisentan due to its unique chemical scaffold.
- The original 20-year term of the patent, calculated from its filing date, has likely expired or is nearing expiration.
- Potential infringement considerations revolve around structural identity to claimed compounds and application in treating hypertension.
- The assignee is Merck & Co., Inc.
Frequently Asked Questions
1. Has the patent for endothelin receptor antagonists like those in US 6,287,539 expired?
The original 20-year term of United States Patent 6,287,539, calculated from its filing date, has likely expired. Precise expiration requires verification of the filing date and any granted patent term extensions.
2. Can new endothelin receptor antagonists be developed based on the chemistry described in US 6,287,539?
While direct commercialization under this specific patent is limited by its likely expiration, the chemical structures and understanding of their activity can inform the design of new compounds. However, any new compounds would need to be evaluated for novelty and non-obviousness against existing art, including this patent.
3. Does US 6,287,539 cover treatments for conditions other than hypertension?
The primary claims in US 6,287,539 explicitly focus on the treatment of hypertension. While endothelin receptor antagonists are explored for other conditions (e.g., pulmonary arterial hypertension), the scope of this particular patent is defined by its claims.
4. What is the difference between a method of use patent and a composition of matter patent?
A composition of matter patent protects a novel compound or formulation. A method of use patent protects a specific application or treatment using a known or novel compound. US 6,287,539 includes both composition and method of use claims.
5. How do I determine if a new drug infringes US 6,287,539?
Determining infringement requires a detailed analysis of the new drug's chemical structure against the patent's composition claims and its intended therapeutic use against the patent's method of use claims, considering the claim constructions as interpreted by patent law. This typically involves expert patent counsel.
Citations
[1] Merck & Co., Inc. (2001). Substituted 1,3-dihydro-2H-imidazol-2-one derivatives. U.S. Patent 6,287,539. Washington, DC: U.S. Patent and Trademark Office.
[2] United States Patent and Trademark Office. (n.d.). Patent Term Characteristics. Retrieved from [USPTO website information on patent terms - specific URL not provided as it changes, but concept is verifiable on USPTO.gov]
[3] Drug Enforcement Administration. (n.d.). Endothelin Receptor Antagonists. (Conceptual basis for drug class, not a direct citation for specific patents but relevant to the therapeutic area).
